Clinical trial registry

Landmark completed trials behind our reporting. Registry identifiers are ClinicalTrials.gov NCT numbers; results links point to the peer-reviewed publications.

NCT03548935 · Completed

STEP 1 — Semaglutide Treatment Effect in People with Obesity

Phase 3 · Randomized, double-blind, placebo-controlled · Enrollment: 1,961

Sponsor: Novo Nordisk · Duration: 68 weeks

Primary outcome: percentage change in body weight with semaglutide 2.4 mg once weekly vs placebo, both with lifestyle intervention

Published in N Engl J Med 2021 (Wilding et al.), doi: 10.1056/NEJMoa2032183

NCT03987919 · Completed

SURPASS-2 — Tirzepatide versus Semaglutide in Type 2 Diabetes

Phase 3 · Randomized, open-label, active-controlled · Enrollment: 1,879

Sponsor: Eli Lilly and Company · Duration: 40 weeks

Primary outcome: change in HbA1c with tirzepatide (5, 10 or 15 mg) vs semaglutide 1 mg once weekly, added to metformin

Published in N Engl J Med 2021 (Frías et al.), doi: 10.1056/NEJMoa2107519

NCT03574597 · Completed

SELECT — Semaglutide Cardiovascular Outcomes Trial in Overweight or Obesity

Phase 3 · Randomized, double-blind, placebo-controlled, event-driven · Enrollment: 17,604

Sponsor: Novo Nordisk · Median follow-up: ~40 months

Primary outcome: time to first major adverse cardiovascular event (cardiovascular death, nonfatal MI, nonfatal stroke) with semaglutide 2.4 mg vs placebo

Published in N Engl J Med 2023 (Lincoff et al.), doi: 10.1056/NEJMoa2307563